A case study examines prescribing and healthcare use in non-hospitalized COVID-19 recovery devices

Severe Acute Respiratory Syndrome In the epidemic of coronavirus disease (COVID-19) caused by coronavirus 2 (SARS-CoV-2), efforts to study the long-term effects of the disease are primarily severe illnesses. We have focused on inpatients who have experienced.

The majority of patients experience only mild symptoms or are asymptomatic. However, it is still unclear whether these patients may still suffer from the persistent effects of infection.

In a new study published in Lancet, A team of researchers investigated the use of prescription drugs and healthcare in people who do not require hospitalization after SARS-CoV-2 infection.

Researchers at the University of Southern Denmark aimed to investigate the effects of mild SARS-CoV-2 infection in patients after recovery from the disease. The team found a low risk of delaying acute complications after mild COVID-19, which does not require hospitalization. However, many of these individuals tend to have persistent symptoms, with more doctors seeing them six months after infection.

COVID-19 Long haul carrier

As the pandemic progressed, many cases of post-viral complications emerged. Long-haul carriers of COVID-19 showed a series of persistent symptoms long after viral clearance. These symptoms include coughing, malaise, body aches, shortness of breath, insomnia, headaches, and brain fog.

Most of the patients who experienced persistent symptoms were hospitalized for moderate to severe COVID-19. These delayed complications include encephalitis, pulmonary fibrosis, thromboembolic events, and psychiatric disorders.

However, there is limited evidence of complications for those who have not been hospitalized.

Increased doctor consultation

The team conducted a population-based cohort study using Danish prescription, patient, and health insurance registries. Overall, the team identified 10,498 patients who were positive for COVID-19 via the reverse transcription-polymerase chain reaction (RT-PCR) test in Denmark between February 27 and May 31, 2020. Identified. Of these, the team tracked 8,983 unhospitalized COVIDs. Between 2 weeks and 6 months after the test, 19 patients and 80,894 COVID-19 negative people.

The team sought to find reports of delayed acute complications, chronic illness, outpatient visits with persistent symptoms, and prescription drug use. They compared the data between the two groups to assess the risk of starting a new drug and getting a diagnosis of a new health condition.

Of the patients infected with COVID-19, 31% started new drug treatment during the follow-up period. The team also found that people who tested positive for SARS-CoV-2 were at higher risk of starting a new drug to dilate the airways and treat migraine headaches, compared to those who tested negative for SARS-CoV-2. Revealed.

In addition, those who tested positive were at increased risk of receiving a hospital diagnosis of dyspnea or shortness of breath and venous thromboembolism compared to those who tested negative.

Patients with COVID-19 received more medical and outpatient visits than individuals who were negative for SARS-CoV-2.

Overall, the absolute risk of hospital visits was low due to delayed acute complications, new onset of chronic illness, and persistent symptoms 2 weeks to 6 months after SARS-CoV-2 infection that did not require hospitalization. ..

However, asymptomatic or mild patients received a hospital diagnosis of dyspnea, developed venous thromboembolism, started bronchodilator treatment, and started triptans compared to patients who were negative for infection. The risk of doing so was still high.

Patients who were positive for SARS-CoV-2 were seen by a doctor after the primary infection than those who were negative. This means that even people who have recovered from mild COVID-19 may have persistent symptoms.